Catalent Biologics Content

  1. Elemental Impurities Risk Assessment For Finished Drug Products

    This webinar reviews the impact of regulatory changes related to elemental impurities testing, guidance on the best routes to compliance, and an overview of the elemental impurities risk assessment process.

  2. Advancements In ADCs Using SMARTag Technology

    SMARTag technology enables site-specific, controlled drug-protein conjugation, and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering.

  3. Biologics Drug Product: Formulation, Tech Transfer, Delivery Strategies

    Review key considerations for formulation screening of therapeutic proteins and how consistency, planning, and communication are essential for a successful biologic drug product tech transfer.

  4. Evolution Of Flexible Commercial Biologics Manufacturing

    Are you achieving optimal flexibility in your biologics development and manufacturing by effectively leveraging the most advanced technologies?

  5. Keys To A Successful Rapid Commercial Launch

    Combining a rapid launch following regulatory approval with effective messaging and post-launch services can provide a competitive advantage.